JMP Securities Reiterates Market Outperform on Karuna Therapeutics, Maintains $318 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler has reiterated a 'Market Outperform' rating on Karuna Therapeutics (NASDAQ:KRTX) and maintained a price target of $318.
November 17, 2023 | 5:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JMP Securities analyst Jason Butler reiterates a 'Market Outperform' rating on Karuna Therapeutics with a maintained price target of $318.
The reiteration of a 'Market Outperform' rating and the maintenance of a high price target by a reputable analyst like Jason Butler could instill confidence in investors and positively influence Karuna Therapeutics' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100